Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxytocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 12/20 | 0.97 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.97 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.97 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytocin SCHEMBL1661474 | 0.99 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL14085374 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL20707334 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL16373316 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL1173243 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL8370159 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL7658368 | 0.97 | OXTR (0.95) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL5110121 | 0.97 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115487167-B | Preparation of multifunctional bionic nano nerve antidote and application of multifunctional bionic nano nerve antidote in Alzheimer disease treatment medicine | 天津医科大学 | 2024-01-26 | — | — | CN | claimed |
| CN-114983935-B | Uterine contraction injection and its preparation process | 上海上药第一生化药业有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115487167-A | Preparation of multifunctional bionic nano nerve antidote and application of multifunctional bionic nano nerve antidote in medicine for treating Alzheimer's disease | 天津医科大学 | 2022-12-20 | — | — | CN | claimed |
| CN-114983935-A | Oxytocin injection and preparation process thereof | 上海上药第一生化药业有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-113694176-A | Application of oxytocin-loaded chitosan nanogel in preparation of early intervention drug for Alzheimer's disease | 天津医科大学 | 2021-11-26 | — | — | CN | claimed |
| CN-113274482-A | Application of oxytocin or derivative thereof in preparation of preparation for treating or improving poor milk and composition | 穆琳 | 2021-08-20 | — | — | CN | claimed |
| CN-113244520-A | Smell transfer module | 杨孟君 | 2021-08-13 | — | — | CN | claimed |
| US-20100143485-A1 | Oxycontin controlled release formulations and methods of using same | SILICON VALLEY BANK | 2010-06-10 | — | — | US | claimed |
| EP-1773870-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | Novetide Ltd. (IL) | 2007-04-18 | — | — | EP | claimed |
| US-20060276626-A1 | Methods for the production of peptide derivatives | TEVA PHARMACEUTICALS USA, INC. | 2006-12-07 | — | — | US | claimed |
| WO-2006119388-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | NOVETIDE, LTD. (IL) | 2006-11-09 | — | — | WO | claimed |
| EP-1605894-A2 | OXYTOCIN CONTROLLED RELEASE FORMULATIONS AND METHODS OF USING SAME | PR Pharmaceuticals (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004078147-A2 | OXYTOCIN CONTROLLED RELEASE FORMULATIONS AND METHODS OF USING SAME | PR PHARMACEUTICALS (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2026106780-A1 | PHYSIOLOGICAL AGING AND REJUVENATION OF VITAL HUMAN ORGAN SYSTEMS IN VITRO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | CAMURUS AB (SE) | 2025-11-13 | — | — | US | disclosed |
| US-20250213648-A1 | OXYTOCIN COMPOSITIONS AND METHODS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2025-07-03 | — | — | US | disclosed |
| WO-2005009356-A2 | METHOD FOR THE PREPARATION OF CONTROLLED RELEASE FORMULATIONS | PR PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009357-A2 | CONTROLLED RELEASE COMPOSITIONS | PR PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004078147-A2 | OXYTOCIN CONTROLLED RELEASE FORMULATIONS AND METHODS OF USING SAME | PR PHARMACEUTICALS (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-0410696-A1 | Mucoadhesive hydrogels delivery system | E.R. SQUIBB & SONS, INC. (US) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | PHOSPHO1, LIPA, ABHD16A | OXTR 3670/4885AVPR1A 593/4885AVPR2 1178/4885 |
| US-20060276626-A1 | Methods for the production of peptide derivatives | VIP, IAPP, PTMS | OXTR 1488/4885AVPR1A 349/4885AVPR2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.